Objectives: Retrospective evaluation of anemia frequency and its prognostic value in patients with different subtypes of nonHodgkin's lymphoma and comparison with other clinical characteristics.
Introduction
Anemia is a common feature in lymphoproliferative diseases, even before patients have received cytotoxic therapy and even when there is no bone marrow involvement. The pathogenesis of this anemia, although unclear, seems to result from multifactorial factors which include bone marrow involvement, abnormal iron reutilization [1, 2] , inappropriately low serum erythropoietin levels for the degree of anemia [3] [4] [5] and a decrease of bone marrow response to erythropoietin [6] [7] [8] . Recent attempts to elucidate the mechanisms of anemia have concentrated on mediators of the inflammatory response that have been shown to inhibit erythropoiesis such as interleukin-1 [9] , y-interferon [10] and tumour necrosis factor [11] [12] [13] .
Many studies [14] [15] [16] have reported the incidence and the prognostic value of bone marrow involvement in the outcome of non-Hodgkin's lymphoma, but few have looked at anemia at diagnosis. Moreover, anemia was not included in the International Prognostic Index study and was not considered according to the different lymphoma subtypes. Yet, it is an old, simple and reproducible variable which is used in the Binet classification [17] , in the Durie and Salmon classification [18] and in the Straus model [19] .
Therefore the prognostic value of anemia was evaluated in 1077 lymphoma patients treated in a single institution according to histology, bone marrow involvement and the international prognostic index.
Patients and methods

Patients
From January 1980 to May 1995, 1375 adult patients were admitted to our centre for diagnosis or treatment of a non-Hodgkin's lymphoma. Patients who were seropositive for the human immunodeficiency virus were excluded. A complete blood count was obtained in 1077 patients at the time of initial staging, and 298 patients were excluded because of previous treatment or missing hematological data. Of the 1077 patients, 587 were males, with a median age of 57 years (range 11-92). Staging included a complete history and physical examination, routine blood tests, chest X-ray, bone marrow biopsy and, in the majority of cases, a thorax and abdomen computerised tomography and a cerebrospinal fluid examination. The Ann Arbor stage [20] , the International Prognostic Index score [21] and the Eastern Cooperative Oncology Group Number of patients with anemia (%) 341 (32) 169 (27) 172 (39) 155 (20) 181 (62) 78 (21) 259 (37) 159 (23) 178 (48) 145 (22) 191 (47) 105 (20) 202 (47) 92 (19) 165 (58) 164 (67) 128 (19) 158 (37) 165 (27) 142 ( (38) 294 (79) 436 (63) 537 (77) 193 (52) 509 (78) 217 (53) 411 (80) 225 (53) 399 (81) 121 (42) 81 (33) 555 (81) 265 (63) 448 (73) 604 ( Table 2) .
Definition of anemia
Anemia was defined as a hemoglobin level less than or equal to 12 g/dl for all men and women over 50 years old and less than or equal to 11 g/dl for women under 50, assessed before treatment initiation.
Methods
Follow-up was obtained for all patients, with a schedule during the first year of a three-month interval which progressively increased thereafter. Complete response was defined as the disappearance of all clinical evidence of disease and normalisation of all biological markers. Overall survival was calculated from the date of diagnosis to the date of last follow-up or death. Progression-free survival was assessed from the beginning of the first treatment until the date of progression. Time to relapse was calculated for complete-remission patients from the beginning of treatment until relapse. Statistical analyses were carried out according to the procedures of the BMDP package. The chi-square test was used to compare the distribution of the different parameters among patients subgroups. A stepwise multiple linear regression method was used to correlate anemia with other variables. Survival curves were generated by the Kaplan-Meier method [24] . The log-rank test was used to compare the distribution of survival times in univariate analysis and to select statistically significant factors. Then, a multivariate analysis was performed using the Cox proportional hazard model [25] .
Results
Incidence of anemia
Anemia was the most common hematologic finding at diagnosis (341 patients, 32%) and varied according to lymphoma histology (Table 2) . Anemia was frequently seen in small lymphocytic or lymphoplasmacytoid lymphoma (37%), mantle-cell (32%), T-cell (28%), diffuse large-cell (39%) and high-grade lymphomas (32%) but less frequently in follicular (17%) and marginal zone lymphomas (19%) (chi-square, P < 0.0001).
According to the patient characteristics (Table 1) , anemia was more common in patients with bone marrow involvement (37% versus 27%, P -0.0005) and half of the patients (49%) had both anemia and bone marrow involvement. Anemia was also significantly associated (P < 0.0001) with age over 60, performance status superior or equal to 2, B symptoms, stage III and IV, bulky tumour, extranodal sites superior or equal to 2, elevated LDH, high (32-microglobulin and creatinin level, low serum albumin. Involvement of spleen (< 0.0001), liver m i Only patients with all available variables were included in the multivariate analysis. Neither advanced stage, B symptoms presence, bulky tumour, bone marrow or spleen involvement nor the presence of two or more extranodal sites of disease were retained as significant in the model. "See Table 3 . (< 0.0001), pleural (< 0.0005), gastro-intestinal tract (< 0.005), CNS (<0.01) or kidney (<0.05) were also associated with the presence of anemia. Thus, anemia was more common in patients who had classic adverse prognostic factors and high-risk I PI score.
To evaluate the clinical factors that might be associated with anemia, a stepwise multiple linear regression analysis was performed (Table 3 ). This showed that anemia was correlated with low serum albumin and high P2-microglobulin levels, spleen involvement and poor performance status. However, age, LDH, bone marrow involvement and high creatinine level were not retained as independent variables.
Prognostic value of anemia
Data on outcome was available for 1066 of the 1077 patients. At the time of analysis, 59% of the patients were alive and 663 (64%) patients had achieved complete remission. Overall median survival, progressionfree survival and relapse-free survival were, respectively, 106, 51 and 121 months, with a median follow-up of 57 months. The rate of complete remission was lower in patients with anemia (P < 0.0001, 53% versus 69%).
In univariate analysis, the overall survival and progression-free survival were significantly shorter for patients who were anemic at diagnosis (P < 0.0001 for both, Figure 1 ) but anemia had a borderline significance for relapse-free survival (P = 0.037). Depending on the presence or absence of anemia, median survival was, respectively, 47 and 146 months for overall survival and 15 and 64 months for progression-free survival. When the impact of anemia on survival was analysed according to the presence or absence of bone marrow involvement, it was found to be highly significant for both overall and progression-free survival {P < 0.0001 for each, Figure 2 ). According to histology (Table 2) , anemia was significantly associated with a shorter overall survival in small^ Figure 2 Overall survival of 419 patients with bone marrow involvement (top curve, a) and of 607 patients without bone marrow involvement (bottom curve, b) according to the presence or absence of anemia (some patients were not evaluable for bone marrow involvement or unavailable for follow-up). P denotes the log-rank test P-value.
lymphocytic or lymphoplasmacytoid, follicular, mantle cell, diffuse large-cell and high-grade lymphomas (Figure 3) and with a shorter progression-free survival in mantle-cell, diffuse large-cell and high-grade lymphomas. Then a multivariate analysis was performed crossing anemia with significant variables for overall and progression-free survival. Anemia was found to be an independent adverse prognostic factor for overall survival (P -0.0001, Table 4 ) and progression-free survival (P = 0.0048, Table 5 ). Anemia remains a prognostic factor for patients with bone marrow involvement for both overall (P -0.007) and progression-free survival (P -0.005). However, in patients without bone marrow involvement, anemia was not retained as a significant independent factor for overall and progression-free survival (not shown).
Finally, the addition of the hemoglobin value to the five variables of the International Prognostic Index improved the predictive value of this index for overall survival (j_ 2 improvement = 12.57; P = 0.0004) and for progression-free survival (x 2 improvement = 12.35; P -0.0004). . Some patients had unclassified histologic subtypes or were unavailable for follow-up. P denotes the log-rank test P-value.
Discussion
The purpose of this retrospective study was to determine at diagnosis the incidence and the prognostic value of anemia in a large group of lymphoma patients. Anemia was present in 32% of our cases. Similar results were found in low-grade lymphomas (29%-37%) [16, [26] [27] [28] as well as in intermediate-and high-grade lymphomas (28%-47%) [29] [30] [31] [32] [33] . A lower incidence, however, was also reported [15, 16, 34, 35] but in association with a lower cut-off point of anemia (^ 9 to 11 g/dl). In our study, the frequency of anemia varied depending on the histology and was low in indolent lymphomas (17% in follicular and 19% in marginal zone lymphomas) except for small lymphocytic or lymphoplasmcytoid (37%). This is not surprising since this entities are closer to chronic lymphoid leukemia in which anemia is frequent. In the other histologic subgroups the incidence of anemia was higher. This might be explained by increased cytokine production. Only two studies have considered the incidence of anemia according to histological subgroups. Conlan et al. [36] found that highgrade lymphoma patients had a lower median hemoglobin value and a higher percentage of anemia than patients with intermediate-and low-grade lymphomas. On the other hand, Bloomfield et al. [26] found no significant difference among histologic types. In our study patients with bone marrow involvement had a significantly higher incidence of anemia (P < 0.0001), as was also reported by Bloomfield et al. [26] . Other studies yielded similar results [36, 37] but the difference was not statistically significant. Interestingly, the results of the multiple regression analysis showed that anemia was not correlated with bone marrow involvement, and the presence of anemia at diagnosis is thus clinically significant irrespective of the presence of bone marrow involvement.
The pathogenesis of anemia in lymphoma is unclear but several mechanisms, such as auto-immune hemolysis and bone marrow involvement, must be considered. Anemia of chronic disease is characterised by bone marrow erythroid hypoplasia, a shortened survival of red cells, and deficient erythropoietin production for the hemoglobin level [6] [7] [8] . This might be associated with a high inflammatory cytokine production by lymphoma or reactive cells. The strong correlation observed between anemia and poor performance status as well as low serum albumin supports this hypothesis. Several studies have showed that inflammatory cytokines such as interleukin-1 [9] and tumour necrosis factor-oc [11] [12] [13] reduce erythropoietin production and inhibit the response of erythroid progenitors to erythropoietin in vitro. Previous clinical observations in lymphoma patients have also indicated an association between elevated plasma tumour necrosis factor-a levels and anemia [38] .
Our data confirmed previous findings [15, 28, 30, 31, 34, 36, 39, 40] that anemia at diagnosis is an adverse prognostic factor for overall survival (P < 0.0001). In addition, anemia was also found to be associated with shorter progression-free survival (P < 0.0001), in contrast to other studies [14, 30] . In our study, anemic patients had a shorter overall survival in all histological subgroups except for marginal zone lymphoma which included only 50 patients. Progression-free survival was also shorter in anemic patients with small lymphocytic or lymphoplasmacytoid, mantle cell, diffuse large-cell and high-grade lymphomas. Irrespective of bone marrow involvement, anemia was found to be associated with shorter overall and progression-free survivals. However, multivariate analysis showed that in patients with bone marrow involvement anemia is more significant, as was also suggested by previous studies [36, 41] .
These results emphasize the importance of anemia as a prognostic factor in non-Hodgkin's lymphomas, particularly in certain histological subgroups and in patients with bone-marrow involvement. The presence of anemia is correlated with other well-known prognostic factors related to the host (albumin and performance status) and the tumour (stage, p2-microglobulin). Anemia will have to be taken into account in future prognostic-factor studies, since hemoglobin value is easy to measure, cheap and easily reproducible.
